TRT Bloodwork: The 12 Labs That Matter, Target Ranges and When to Test
TRT Bloodwork: The 12 Labs That Matter, Target Ranges and When to Test
TRT bloodwork is the set of blood tests used before and during testosterone replacement therapy to confirm the diagnosis, prove the dose is working, and catch the side effects that show up in blood long before they cause symptoms. Testosterone itself is only one of them. The two professional guidelines that govern TRT (Endocrine Society 2018, American Urological Association 2018) name specific labs, specific thresholds and a specific schedule. This guide lists all of them with the numbers.
Educational content. MuscleScience does not prescribe, sell or supply testosterone and does not interpret individual lab results. Diagnosis, dosing and lab interpretation belong with a licensed clinician.
TRT Bloodwork: 3 Numbers the Guidelines Agree On
Most confusion about TRT labs comes from forums, not from the guidelines. The Endocrine Society and the AUA disagree on a few details, but on the three numbers that drive most clinical decisions they line up almost exactly.
Both guidelines treat a hematocrit above 54 percent as the point where therapy is paused or the dose reduced, and hypoxia or sleep apnea is looked for. The Endocrine Society also advises against starting TRT at all when baseline hematocrit is already above 48 percent (50 percent at high altitude).
The Endocrine Society aims for the mid-normal range; the AUA states it as 450 to 600 ng/dL. The harmonized normal range for healthy non-obese men aged 19 to 39 is 264 to 916 ng/dL (Travison 2017), so a "high-normal" reading is not the goal of therapy.
The Endocrine Society schedule is: baseline, a review at 3 to 12 months after starting, then annually. Hematocrit specifically at baseline, 3 to 6 months and then every year. PSA (men 40 and older with a baseline PSA above 0.6 ng/mL) at baseline and 3 to 12 months, then per screening guidance.
The one lab everyone checks, total testosterone, is also the one most often mistimed. For injectable cypionate or enanthate the guideline instruction is to draw the sample midway between injections, at a consistent point in the cycle, and to aim for the mid-normal range at that point. A peak-timed draw the day after an injection is not comparable with a trough draw a week later.
The full baseline panel: 12 tests, what each one answers, and which of them the guidelines actually require.
Target ranges for testosterone on therapy, and the action thresholds for hematocrit, PSA and estradiol.
The monitoring schedule from the Endocrine Society guideline, laid out by visit.
The five mistakes that make TRT labs unreadable: timing, single draws, assay choice, chasing estradiol, and skipping the CBC.
The 12 TRT Blood Tests: What Each One Answers
A baseline is not optional. Once testosterone is started, LH and FSH are suppressed, hematocrit drifts up and estradiol rises with it, so anything not measured before the first dose can never be separated from the effect of the drug. The table lists the panel used before starting and repeated, in part, on therapy. Status shows how firmly each test is anchored in the guidelines.
| Test | What it answers | Numbers to know | Status |
|---|---|---|---|
| Total testosterone | Is the diagnosis real, and is the dose landing in range? | Two separate morning (7 to 10 am) fasting draws for diagnosis. Cutoff: 264 ng/dL (Endocrine Society, harmonized range) or 300 ng/dL (AUA). On therapy: mid-normal, AUA 450 to 600 ng/dL. | ● Required |
| Free testosterone | How much testosterone is biologically available when SHBG is high or low. | Measure by equilibrium dialysis or calculate from total T, SHBG and albumin. Direct analog immunoassays are inaccurate and are discouraged by both guidelines. | ● When SHBG is abnormal |
| SHBG | Explains why total and free testosterone disagree. | Rises with age, thyroid excess and liver disease; falls with obesity, insulin resistance and androgens. Needed for any free testosterone calculation. | ● When SHBG is abnormal |
| LH and FSH | Primary (testicular) versus secondary (pituitary) hypogonadism. | High LH with low T points to the testes; low or normal LH with low T points to the pituitary or hypothalamus and needs a workup. Only meaningful at baseline: TRT suppresses both. | ● Required at baseline |
| Prolactin | Rules out a pituitary cause when LH is low or inappropriately normal. | Endocrine Society: measure in secondary hypogonadism. A markedly raised prolactin or a very low T (below about 150 ng/dL) prompts pituitary imaging. | ● Secondary hypogonadism |
| Estradiol (E2) | How much testosterone is aromatizing; context for breast tenderness, mood and fluid changes. | Ask for LC-MS/MS, not a standard immunoassay, which overreads at male concentrations. Neither guideline recommends routine aromatase inhibitors on TRT. | ● Symptom-driven |
| CBC: hemoglobin and hematocrit | Is testosterone driving red-cell production too far? | Baseline, 3 to 6 months, then annually. Action at hematocrit above 54 percent. Do not start above 48 percent (Endocrine Society). | ● Required |
| PSA | Prostate safety baseline and change over time. | Men 40 and older (AUA), or 40 and older with baseline PSA above 0.6 ng/mL (Endocrine Society). Urology referral if PSA rises more than 1.4 ng/mL in any 12 months, or exceeds 4.0 ng/mL at any time. | ● Required from age 40 |
| Lipid panel | Cardiovascular context; injectable and oral androgens can lower HDL. | Total cholesterol, LDL, HDL, triglycerides. Compare against the baseline draw, not against a population range. | ● Context |
| Liver enzymes (ALT, AST, GGT) | Liver context; relevant mainly for oral 17-alpha-alkylated androgens, which TRT does not use. | AST and ALT also rise after hard training because both are in muscle. GGT separates liver from muscle. | ● Context |
| Kidney markers (creatinine, eGFR, BUN) | Kidney context; creatinine runs high in muscular men. | Cystatin C is a better filter marker when muscle mass is high. Hydration and creatine supplements shift creatinine too. | ● Context |
| Fasting glucose and HbA1c | Metabolic context; obesity and insulin resistance both lower SHBG and total testosterone. | Low testosterone with a high HbA1c is often a weight problem first. Both guidelines list weight loss as a reversible cause to address. | ● Context |
Two things that are not blood tests still belong on the same sheet: blood pressure, which testosterone can raise through fluid retention and hematocrit, and a symptom score, because a lab result that improves without any change in the symptoms that justified treatment is a reason to reconsider, not to raise the dose. For a walkthrough of the individual markers, see total vs free testosterone, SHBG explained, the CBC markers guide and the lipid panel guide.
Where Testosterone Should Sit on TRT, and When to Draw It
The chart puts the guideline numbers on one scale. The diagnostic cutoffs sit at the bottom of the normal range; the treatment target sits in the middle of it, not at the top. A trough reading of 900 ng/dL is above target for both guidelines, whatever a forum says about "optimal".
Timing depends on the form of testosterone. For cypionate or enanthate injections, sample midway between injections; for a weekly schedule that is day 3 or 4. For daily gels, sample 2 to 8 hours after application, on a day the gel was applied as usual. For pellets, sample at the end of the dosing interval. For nasal or short-acting oral products, the assay is timed to the product label. Whichever form is used, the rule that matters is consistency: the same day of the cycle, the same time of morning, fasting, and the same laboratory, so that results are comparable across visits. How dosing frequency changes the peak-to-trough swing is covered in TRT injection frequency.
A different view: what changes on testosterone in randomized trials. Calof 2005 pooled 19 placebo-controlled trials in men over 45 (651 on testosterone, 433 on placebo). Bars show the odds ratio versus placebo; 1.0 means no difference.
The pattern explains the priorities in the monitoring schedule: the most frequent adverse effect of testosterone in trials is a rise in hematocrit, and the "prostate events" signal is mostly a detection effect (more PSA testing and biopsies), not more cancer. Both are lab-visible, which is why the CBC and PSA are the tests the guidelines schedule most deliberately.
4 TRT Lab Results That Change the Plan
Most results on a TRT panel are read as trends. Four of them have hard thresholds in the guidelines, where a specific number triggers a specific action rather than a conversation.
Hematocrit above 54 percent: pause or reduce
Testosterone stimulates erythropoietin and suppresses hepcidin, so red-cell mass rises in almost everyone, and further in men using injections, at higher doses, and in older men (Coviello 2008, Ohlander 2018). Above 54 percent the Endocrine Society advises stopping until hematocrit falls to a safe level, evaluating for hypoxia and sleep apnea, and restarting at a lower dose. Switching from a long injection interval to smaller, more frequent doses, or from injections to a transdermal, lowers the peak that drives the rise. Full detail in high hematocrit on TRT.
PSA rise above 1.4 ng/mL in a year, or above 4.0: urology referral
Testosterone does not appear to cause prostate cancer in the trial data (Cui 2014: 22 randomized trials, 2,351 men, no increase in cancer or progression), but it can raise PSA modestly in the first months and can unmask an existing tumor. The Endocrine Society referral triggers are a confirmed PSA above 4.0 ng/mL at any time, a rise of more than 1.4 ng/mL within any 12-month period, an abnormal digital rectal exam, or a prostate symptom score above 19. A 40-year-old with a baseline PSA of 0.4 ng/mL is a different risk conversation from a 62-year-old at 2.8.
Testosterone above the target range at trough: reduce the dose
A supraphysiological trough is the most common finding in men who feel "great" on therapy and are surprised by their hematocrit. The correction is a lower dose or a longer interval, not an aromatase inhibitor. Persistently low troughs with good peaks mean the interval is too long for the ester, which is a frequency problem, not a dose problem.
Symptoms without lab change, or lab change without symptoms: reassess the diagnosis
The Endocrine Society is explicit that therapy is continued on the basis of symptom response and absence of adverse effects, evaluated at 3 to 12 months. A man whose testosterone is now 550 ng/dL and who feels no different from baseline probably never had testosterone deficiency as the cause of his symptoms. Sleep apnea, depression, thyroid disease, medication effects and obesity all produce the same complaint list.
Estradiol on TRT Bloodwork: Measure It Properly, Then Mostly Leave It Alone
Estradiol rises on testosterone because a fraction of the dose is aromatized, and the rise is roughly proportional to the testosterone level. That is not a malfunction. In Finkelstein's 2013 dose-response study in healthy men, blocking aromatization while giving testosterone increased body fat and reduced sexual function, which is the experimental proof that men need their estradiol. Neither TRT guideline recommends measuring estradiol routinely, and neither recommends an aromatase inhibitor as part of standard therapy.
When estradiol is measured, the assay matters more than the number. Standard estradiol immunoassays were built for female concentrations and over-read badly in the male range, which is where most of the "my E2 is 60" panic comes from. Ask for estradiol by LC-MS/MS (sometimes labelled "sensitive" or "ultrasensitive"). Interpret it next to the testosterone drawn in the same sample: an estradiol of 45 pg/mL with a trough testosterone of 850 ng/dL is a dose that is too high, not an estrogen problem. The E2 to testosterone ratio calculator does that arithmetic, and estradiol on TRT covers the symptom side in detail.
Crushing estradiol with an aromatase inhibitor produces joint pain, low libido, poor erections, flat mood, poor sleep and, over years, bone loss. Those symptoms overlap with "high estrogen" complaints, which is how men end up on an aromatase inhibitor for symptoms the inhibitor is causing. If a number needs fixing, the tool is the testosterone dose.
LH, FSH and Sperm: The Labs TRT Turns Off
Exogenous testosterone shuts down the pituitary signal. LH and FSH fall to near zero within weeks, intratesticular testosterone collapses, and sperm production follows. In a Canadian fertility-clinic series (Samplaski 2014), 88 percent of men who were taking testosterone were azoospermic; about 65 percent of those without another cause had recovered sperm production within 6 months of stopping, which means about a third had not. Both guidelines therefore list a desire for fertility in the near term as a reason not to start TRT and to consider clomiphene or hCG instead.
On bloodwork this means two things. LH and FSH are only interpretable at baseline; a suppressed LH on therapy tells you nothing except that the testosterone is being absorbed. And if fertility matters at all, a semen analysis before the first dose is the baseline that no later lab can replace. The TRT and fertility question is covered in TRT and fertility, and how recovery of the axis works after exogenous androgens is covered in TRT vs steroid cycles.
TRT Bloodwork Schedule by Visit (Endocrine Society 2018)
The table condenses the guideline monitoring recommendations into a visit plan. Individual clinics add tests or shorten intervals; few should be doing less than this.
| Visit | Labs | Decision being made | Status |
|---|---|---|---|
| Before starting | Total T x2 (morning, fasting), LH, FSH, SHBG and free T if indicated, prolactin if LH is low, CBC, PSA and DRE (from 40), lipids, CMP, HbA1c, blood pressure, symptom score; semen analysis if fertility matters | Confirm deficiency; classify primary vs secondary; exclude contraindications (hematocrit above 48 percent, untreated severe sleep apnea, prostate or breast cancer, planned fertility, uncontrolled heart failure, recent cardiovascular event) | ● Guideline |
| 3 to 6 months | Total T (timed to the product), CBC; PSA at 3 to 12 months if it was measured at baseline | Is the dose landing mid-normal? Has hematocrit crossed 54 percent? Has PSA moved more than 1.4 ng/mL? | ● Guideline |
| 3 to 12 months | Symptom review, adverse-effect review, the labs above; estradiol (LC-MS/MS) if there are symptoms suggesting it | Continue, adjust or stop based on symptom response plus labs | ● Guideline |
| After any dose or product change | Total T and CBC, 6 to 12 weeks after the change once the new steady state is reached | Confirm the change did what it was meant to | ● Practice |
| Annually, once stable | Total T, CBC, PSA per age-based screening, lipids, CMP, HbA1c, blood pressure; bone density at 1 to 2 years if osteoporosis or a fragility fracture was present at baseline | Long-term safety; whether treatment is still justified | ● Guideline |
Cardiovascular context sits behind the whole schedule. The TRAVERSE trial (Lincoff 2023, 5,246 men aged 45 to 80 with existing heart disease or high risk) found no increase in major cardiovascular events on testosterone gel versus placebo over about 33 months, but did see more atrial fibrillation, acute kidney injury and pulmonary embolism. None of those is caught by a testosterone level; blood pressure, the CBC and the kidney markers are the labs that cover that territory. The blood pressure on TRT guide and the kidney markers guide go deeper.
5 Mistakes That Make TRT Bloodwork Unreadable
1. One draw, wrong time. A single testosterone result taken at a random point in the injection cycle cannot be compared with anything. Diagnosis needs two morning draws; monitoring needs a fixed point in the cycle.
2. The wrong free testosterone assay. Direct analog free testosterone immunoassays are inaccurate enough that both guidelines advise against them. Use equilibrium dialysis or a calculated value from total T, SHBG and albumin; the free androgen index calculator gives a rough screen from the same inputs.
3. Estradiol by immunoassay, then an aromatase inhibitor. The over-reading assay creates the "high estrogen" that the inhibitor is then prescribed for. LC-MS/MS first; dose adjustment second; inhibitor rarely.
4. Skipping the CBC because "I feel fine". Hematocrit at 56 percent produces no symptoms in most men. It is the most common lab abnormality on TRT and the one with the clearest action threshold, and it is invisible without a blood count.
5. Reading TRT labs with a steroid-cycle mindset. Therapeutic testosterone aims at the middle of the normal range at trough. The peak-and-trough reading habits, liver panels and "on-cycle" ranges from the enhanced side of the site are a different context; blood tests before steroids covers that one separately.
TRT Bloodwork: Common Questions
What blood tests are needed for TRT?
Before starting: two morning total testosterone tests, LH and FSH, a CBC for hemoglobin and hematocrit, PSA from age 40, and usually SHBG, a lipid panel, liver and kidney markers and HbA1c. Prolactin is added when LH is low, and a semen analysis when fertility matters. On therapy the core repeat tests are total testosterone, CBC and PSA.
How often should bloodwork be done on TRT?
The Endocrine Society schedule is a baseline, a review at 3 to 12 months after starting, then once a year. Hematocrit is checked at baseline, at 3 to 6 months and then annually. Most clinics repeat testosterone and a CBC 6 to 12 weeks after any dose change.
What should testosterone levels be on TRT?
In the mid-normal range at the timed sample: the AUA states 450 to 600 ng/dL, and the harmonized normal range for young healthy men is 264 to 916 ng/dL. For injections the sample is drawn midway between doses. A trough above 900 ng/dL is above target for both guidelines.
When should I get bloodwork after a testosterone injection?
Midway between injections, at the same point every time. On a weekly schedule that is day 3 or 4; on a twice-weekly schedule, just before the next dose. A sample 24 hours after an injection captures the peak and will read high.
What hematocrit level is too high on TRT?
Above 54 percent, both major guidelines advise pausing therapy or reducing the dose and checking for sleep apnea or another cause of low oxygen. The Endocrine Society also advises not starting TRT when baseline hematocrit is already above 48 percent.
Should estradiol be tested on TRT?
Not routinely; neither guideline requires it. When symptoms suggest an estrogen effect, test it by LC-MS/MS rather than a standard immunoassay, and read it next to the testosterone from the same draw. A high estradiol with a high trough testosterone is a dose problem.
Does TRT raise PSA?
It can raise PSA modestly in the first months and can reveal an existing prostate cancer, though pooled trials do not show that it causes cancer. Referral to urology is advised if PSA rises by more than 1.4 ng/mL within 12 months or exceeds 4.0 ng/mL.
Do I need to fast for TRT bloodwork?
Yes for the diagnostic draws: the Endocrine Society specifies morning, fasting samples because eating lowers testosterone for a few hours. Fasting also makes the glucose and lipid results usable. Keep the same conditions for every follow-up so results are comparable.
References
Related TRT Guides
Final Educational Note
This article summarizes published clinical guidelines and trials for educational purposes. Reference ranges, cutoffs and monitoring intervals vary between laboratories, countries and clinics, and the numbers here are not a substitute for the interpretation of your own results by the clinician who ordered them.
MuscleScience does not prescribe or supply testosterone. For the wider series, start at the TRT and hormones hub and the bloodwork and health hub.
